Skip to search formSkip to main contentSkip to account menu

LY335979

Known as: LY 335979 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

zosuquidar trihydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The inhibitory and combinative mechanism of HZ08 with P-glycoprotein expressed on the membrane of Caco-2 cell line.
Highly Cited
2011
Highly Cited
2011
Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1)
Tamoxifen is widely prescribed to patients with estrogen receptor-positive breast cancer, and it is a prodrug that requires… 
Highly Cited
2008
Highly Cited
2008
Characterization of Substrates and Inhibitors for the In Vitro Assessment of Bcrp Mediated Drug–Drug Interactions
PurposeIn vitro assessment of drug candidates' affinity for multi-drug resistance proteins is of crucial importance for the… 
2008
2008
Role of xenobiotic efflux transporters in resistance to vincristine.
2005
2005
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours
AbstractBackgroundZosuquidar (LY335979) is an oral P-glycoprotein modulator. This phase I study was designed to determine the… 
Highly Cited
2004
Highly Cited
2004
Contributions of CYP3A4, P-glycoprotein, and Serum Protein Binding to the Intestinal First-Pass Extraction of Saquinavir
Using CYP3A4-expressing Caco-2 cell monolayers, we assessed the roles of CYP3A4-mediated metabolism, P-glycoprotein (P-gp… 
2004
2004
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
PURPOSE Our intention was to (a) to investigate the safety and tolerability of a potent P-glycoprotein modulator, zosuquidar… 
2003
2003
A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)
Abstract Purpose. To develop a population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of zosuquidar… 
2002
2002
Characterization of a novel 99mTc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity.
Multidrug resistance (MDR) mediated by overexpression of MDR1 P-glycoprotein (Pgp) is one of the best characterized barriers to… 
1998
1998
Liquid chromatography/nuclear magnetic resonance spectroscopy and liquid chromatography/mass spectrometry identification of novel metabolites of the multidrug resistance modulator LY335979 in rat…
Compound LY335979 is a P-glycoprotein inhibitor currently entering phase I clinical trials for potential reversal of multidrug… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)